Last week Kyle Bass and Erich Spangenberg, who have upset the pharmaceutical industry by filing more than 30 challenges to issued pharmaceutical patents at the U.S. Patent and Trademark Office, filed two more petitions to invalidate patents owned by two separate pharmaceutical companies. Only this time, the petitions were filed by Bass and Spangenberg as individuals and not by the Coalition for Affordable Drugs, the organization they created earlier this year to challenge pharma patents.

Why the change?

“These are—to borrow a phrase from my good friends at Jones Day and Celgene—truly altruistic filings,” said Spangenberg, using the same language included in briefs filed by another pharma patent holder alleging that the coalition's motives were not altruistic, as had been claimed, but were a “pretext” to benefit Bass' investments.